Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017 Mar; 76(3):534-542.
-
Adult
-
Adult
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Humanized
-
Diarrhea
-
Diarrhea
-
Female
-
Female
-
Headache
-
Headache
-
Humans
-
Humans
-
Injections, Subcutaneous
-
Injections, Subcutaneous
-
Interleukin-6
-
Interleukin-6
-
Lupus Erythematosus, Systemic
-
Lupus Erythematosus, Systemic
-
Male
-
Male
-
Middle Aged
-
Middle Aged
-
Nausea
-
Nausea
-
Pulmonary Embolism
-
Pulmonary Embolism
-
Sepsis
-
Sepsis
-
Severity of Illness Index
-
Severity of Illness Index
-
Symptom Flare Up
-
Symptom Flare Up